Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab for severe pruritus in adults on hemodialysis with chronic kidney disease
2021-004766-35Phase 2Active
- Sponsor
- Galderma
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nemolizumab in chronic kidney disease (CKD) and pruritus (3 arms), sponsored by Galderma. Primary endpoint: Proportion of subjects with improvement in WI-NRS of at least 4 points from baseline at Week 12. Started Apr 2022; status: active.
02
Drugs
nemolizumab
03
Conditions
chronic kidney disease (CKD)pruritus
Beyond the preview
Go deeper on 2021-004766-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004766-35.